Sigilon Therapeutics (SGTX) Stock Price, News & Analysis

Company Overview

Sigilon Therapeutics, Inc., a preclinical stage biotechnology company, develops functional cures for patients with acute and chronic diseases. Its lead product candidate is SIG-002 to replace islet cells for the treatment of type 1 diabetes; and SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-205, SIG-218, SIG-220, and SIG-005, which are to treat the non-neurological manifestations of mucopolysaccharidosis type 1; and SIG-207 is to treat of Fabry disease. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $22.09 to $23.10
• 50-Day Range: $20.92 to $23.06
• 52-Week Range: $3.77 to $28.00
• Volume: 83,600 shs
• Average Volume: 62,902 shs
• Market Capitalization: $56.40 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SGTX Stock Analysis - Frequently Asked Questions

How were Sigilon Therapeutics' earnings last quarter?

Sigilon Therapeutics, Inc. (NASDAQ:SGTX) announced its earnings results on Wednesday, November, 10th. The company reported ($8.19) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($8.58) by $0.39. The firm had revenue of $1.95 million for the quarter, compared to analyst estimates of $3.20 million. Sigilon Therapeutics had a negative net margin of 171.29% and a negative trailing twelve-month return on equity of 83.07%.

When did Sigilon Therapeutics' stock split?

Sigilon Therapeutics shares reverse split before market open on Tuesday, May 23rd 2023. The 1-13 reverse split was announced on Tuesday, May 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

When did Sigilon Therapeutics IPO?

Sigilon Therapeutics (SGTX) raised $101 million in an initial public offering (IPO) on Friday, December 4th 2020. The company issued 5,600,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley, Jefferies, Barclays and Canaccord Genuity served as the underwriters for the IPO.

What other stocks do shareholders of Sigilon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Sigilon Therapeutics investors own include Tesla (TSLA), NIO (NIO), Athenex (ATNX), Plug Power (PLUG), CrowdStrike (CRWD) and Li Auto (LI).

Company Calendar

• Last Earnings: 11/10/2021
• Today: 12/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:SGTX
• CUSIP: N/A
• CIK: 1821323
• Web: sigilon.com
• Phone: 617-336-7540
• Fax: N/A
• Employees: 62
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($12.2328)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-43,560,000.00
• Net Margins: -171.29%
• Pretax Margin: -171.29%
• Return on Equity: -83.07%
• Return on Assets: -38.17%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.78
• Quick Ratio: 1.78

Sales & Book Value

• Annual Sales: $12.94 million
• Price / Sales: 4.36
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $15.68 per share
• Price / Book: 1.43

Miscellaneous

• Outstanding Shares: 2,510,000
• Free Float: 2,351,000
• Market Cap: $56.40 million
• Optionable: Not Optionable
• Beta: 4.12